Vectus Biosystems Ltd (ASX: VBS) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Vectus Biosystems Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$14.63 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
53.21 million
Earnings per share
-0.044
Dividend per share
N/A
Year To Date Return
-8.33%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Vectus Biosystems Ltd (ASX: VBS)
Latest News
Healthcare Shares
Why is this ASX biotech share leaping 14% today?
VBS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Vectus Biosystems Ltd
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.
VBS Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 19 Apr 2024 | $0.28 | $0.04 | 16.67% | 2,000 | $0.25 | $0.28 | $0.25 |
| 18 Apr 2024 | $0.24 | $-0.01 | -4.00% | 24,065 | $0.25 | $0.25 | $0.24 |
| 17 Apr 2024 | $0.25 | $0.00 | 0.00% | 24,700 | $0.25 | $0.25 | $0.25 |
| 15 Apr 2024 | $0.25 | $-0.01 | -3.92% | 12,665 | $0.25 | $0.25 | $0.25 |
| 12 Apr 2024 | $0.26 | $0.01 | 4.08% | 2,000 | $0.26 | $0.26 | $0.26 |
| 10 Apr 2024 | $0.25 | $-0.04 | -14.29% | 16,762 | $0.27 | $0.27 | $0.25 |
| 09 Apr 2024 | $0.28 | $0.04 | 16.67% | 13,612 | $0.27 | $0.29 | $0.27 |
| 03 Apr 2024 | $0.24 | $-0.03 | -11.11% | 67,136 | $0.25 | $0.25 | $0.24 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 04 Dec 2023 | Karen Duggan | Issued | 19,842 | $6,250 |
As advised by the company. Bonus
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Maurie Stang | Non-Executive Deputy ChairmanNon-Executive Director | Dec 2005 |
Mr Stang has more than three decades of experience building and managing companies in the healthcare and biotechnology industry in Australia and internationally. His strong business development and marketing skills have
resulted in the successful commercialisation of intellectual property across global markets. |
| Dr Ronald Cecil Shnier | Non-Executive DirectorNon-Executive Chairman | Sep 2015 |
Dr Shnier completed his radiology fellowship at Royal Prince Alfred Hospital (RPAH) before undertaking his neuroradiology fellowship at RPAH in 1989 and musculoskeletal fellowship at the University of California Los Angeles. He was a consultant specialist at RPAH. Dr Shnier started one of Australia's first Private MRI practices before becoming General Manager of Mayne's Diagnostic Imaging and was its National Director for many years. He has served on several international MRI advisory boards. Dr Shnier has a strong involvement in clinical research and has lectured both in Australia and overseas. He is currently the Chief Medical
Officer of I-MED Radiology network. |
| Dr Susan Margaret Pond | Non-Executive Director | May 2016 |
Dr Susan Pond has a scientific and commercial background, having held executive positions in the biotechnology and pharmaceutical industry for 12 years, including as Chairman and Managing Director of Johnson & Johnson Research Pty Limited. Dr Pond has held many Board positions such as: Non-Executive Director and Chairman of AusBiotech Limited; Director of the Australian Nuclear Science and Technology Organisation; Board member of Innovation Australia; and Vice President of the
Academy of Technological Sciences and Engineering. She is a Fellow of ATSE, the Australian Institute of Company Directors, and the Academy of Health and Medical Sciences. |
| Dr Karen Annette Duggan | Chief Executive OfficerExecutive Director | Sep 2006 |
Dr Duggan was formally director of the Hypertension. Service - Southwestern Sydney Area Health Service (SWSAHS) and is the immediate past chair of the National Blood Pressure and Vascular Disease Advisory Committee. Dr Duggan was also a member of the Cardiovascular Health Advisory Committee of the National Heart Foundation of Australia, the Post-Acute Stroke Guidelines Advisory Committee of the Australian
Government Department of Health and Aging and the Cardiovascular Clinical Expert Reference Group of the NSW Department of Health. |
| Mr Robert John Waring | Company Secretary |
-
|
|
| Robert John Waring | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Kefford Holdings Pty Ltd <The Kefford Family A/C> | 4,770,000 | 8.97% |
| HSBC Custody Nominees (Australia) Limited | 3,341,648 | 6.28% |
| Ajjika Technology Pty Limited <The Ajjika A/C> | 3,200,000 | 6.02% |
| Bernard Stang | 2,676,500 | 5.03% |
| Energy Trading Systems Pty Ltd <The Mpf A/C> | 2,562,500 | 4.82% |
| Maurie Stang | 2,285,952 | 4.30% |
| Gleneagle Securities Nominees Pty Limited | 1,611,596 | 3.03% |
| Bennelong Resources Pty Ltd <John Egan Super Fund A/C> | 1,500,000 | 2.82% |
| Spinite Pty Ltd | 1,435,773 | 2.70% |
| Grizzly Holdings Pty Limited | 1,407,035 | 2.65% |
| Citicorp Nominees Pty Limited | 1,362,470 | 2.56% |
| Truebell Capital Pty Ltd <Truebell Investment Fund> | 1,269,526 | 2.39% |
| Esklaw Pty Ltd <Tom Forrester Family A/C> | 1,000,000 | 1.88% |
| Buttonwood Nominees Pty Ltd | 795,190 | 1.50% |
| T S Rai 2 Pty Ltd <Websta Super Fund A/C> | 700,000 | 1.32% |
| Gleneagle Securities (Aust) Pty Ltd | 638,675 | 1.20% |
| Tdf Properties Pty Ltd <The Tdf Property A/C> | 599,339 | 1.13% |
| Benlee Company Pty Ltd <The Benlee A/C> | 594,398 | 1.12% |
| Gleneagle Securities (Aust) Pty Ltd <House Prop A/C> | 570,000 | 1.07% |
| Satwant Kaur Rai | 550,000 | 1.03% |
